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Summary
Objective: To examine the efﬁcacy and safety of two doses of long-acting acetaminophen in patients with osteoarthritis (OA) of the hip or knee.
Methods: This multicenter, randomized, double-blind, parallel-group, placebo-controlled study evaluated the efﬁcacy and safety of acetamin-
ophen extended-release (ER) 650 mg and 1300 mg given three times daily for the treatment of moderate to moderately severe OA of the hip or
knee. Primary efﬁcacy end points were mean change from baseline through 12 weeks in the Western Ontario and McMaster Universities
Osteoarthritis Index pain and physical function subscale scores and mean patient global assessment of response to therapy at week 12. Safety
assessments included monitoring vital signs, adverse events, study joint assessments, and clinical laboratory results at each study visit.
Results: Four hundred eighty-three patients were randomized to treatment and included in the intent-to-treat analysis. All groups were similar
with respect to baseline demographics except for gender, weight, and body mass index. Acetaminophen ER 3900 mg was signiﬁcantly supe-
rior to placebo for all three primary end points; acetaminophen ER 1950 mg was signiﬁcantly superior to placebo only with respect to patient
assessment of response to therapy. Study treatments were generally well tolerated, and there was no signiﬁcant difference among the groups
in the overall number of adverse events.
Conclusions: Acetaminophen ER 3900 mg/d administered for up to 12 weeks was effective in treating moderate to moderately severe chronic
OA pain of the hip or knee and was generally well tolerated.
ª 2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a rheumatic disease characterized by
articular cartilage degeneration, bone hypertrophy, crepitus,
and radiographic changes that is estimated to affect nearly
20% of Americans1,2. The joint pain and stiffness associ-
ated with OA can lead to signiﬁcant disability and functional
impairment. Among the elderly, OA of the knee is the lead-
ing cause of chronic disability; an estimated 100,000 people
in the United States are unable to walk independently from
bed to bathroom because of knee or hip OA3. Therefore,
controlling these symptoms is critically important to
treatment.
The cost of illness resulting from direct expenditures for
medical care services associated with OA and/or costs re-
sulting from the indirect impact of illness on function are
substantial. In 1992, total direct and indirect costs associ-
ated with treatment of arthritis in the United States were
$64.8 billion; $15.2 billion for medical costs, and $49.6 bil-
lion for costs that resulted from lost productivity4. Since
half of these patients have clinically diagnosed OA, these
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estimates2,5e7.
Acetaminophen extended-release (ER) is a long-acting
analgesic and antipyretic medication indicated for the tem-
porary relief of minor aches and pains caused by arthritis,
the common cold, headache, toothache, muscular aches,
backache, and menstrual cramps8. Acetaminophen ER
caplets contain acetaminophen 650 mg in a bilayer form
that has both immediate-release (IR) and ER components.
In various studies9e11, acetaminophen has been shown to
be comparable to nonsteroidal antiinﬂammatory drug
(NSAID) treatments for the relief of mild to moderate joint
pain associated with OA. However, limited data from well-
designed, placebo-controlled studies are available.
This 12-week study was conducted to evaluate the efﬁ-
cacy and safety of two doses of a formulation of acetamin-
ophen not previously evaluated: acetaminophen ER
650 mg and 1300 mg administered three times a day com-
pared with placebo for the treatment of moderate to moder-
ately severe pain associated with OA of the hip or knee.
Based on the authors’ clinical experience, OA patients
are not always compliant with acetaminophen dosed four
times daily, which may lead to inadequate therapeutic re-
sponse. The purpose of this acetaminophen formulation is
to reduce the number of daily doses required to achieve
the maximum therapeutic dose of acetaminophen. It is
expected that dosing three times daily will improve4
455Osteoarthritis and Cartilage Vol. 15, No. 4compliance and allow the therapeutic program to reach the
maximum effective dose.
Methods
PATIENT POPULATION
Four hundred eighty-three patients 40 years of age or
older who experienced at least moderate pain when not tak-
ing any analgesic medication for OA of the hip or knee were
enrolled in this study. Clinical inclusion criteria were the
presence of symptomatic idiopathic OA of the hip or knee
for a minimum of 6 months with a history of hip or knee
pain requiring the use of NSAIDs, acetaminophen, or other
analgesic agent on a regular basis (3 or more days per
week) for at least 3 months before the screening visit. Pa-
tients must also have had a history of positive therapeutic
beneﬁt with acetaminophen use for OA pain. This study
was conducted to evaluate the efﬁcacy of a formulation of
acetaminophen not previously evaluated in hip or knee
OA. The requirement of a response to acetaminophen
was felt to be appropriate in this setting and is analogous
to the ‘‘ﬂare’’ design used in most trials of antiinﬂammatory
agents. In addition, patients must have reported maximum
OA pain intensity experienced during the 24 h prior to the
baseline visit at a pain level of moderate (2) or moderately
severe (3) on a 5-point Likert scale deﬁned as none (0),
mild (1), moderate (2), moderately severe (3), or severe
(4). If qualifying with OA of the knee, patients had to have
knee pain and radiographic osteophytes, and fulﬁlled at
least one of the following three criteria: experienced morn-
ing stiffness of less than 30 min of duration, experienced
crepitus on motion, or been at least 40 years of age12. If
qualifying with OA of the hip, patients must have had hip
pain, radiographic femoral and/or acetabular osteophytes,
and radiographic joint-space narrowing as established by
the American College of Rheumatology (ACR) criteria for id-
iopathic OA of the hip13. Patients must also have demon-
strated an increase in the Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) pain subscale
score of at least 20% relative to the screening visit score.
All women of childbearing potential were required to have
a negative urine pregnancy test and used an effective
method of birth control during the study.
A patient was excluded from the study if there was a his-
tory of surgery or major trauma to the study joint in the 6
months prior to the screening visit. Patients taking analgesic
therapy for other indications, or those taking anticoagulants,
psychotherapeutic agents, aspirin in daily doses greater
than 325 mg, or statin-class hypolipidemic agents in doses
that had not been stabilized within 3 months of the screen-
ing visit were also excluded. In addition, patients taking glu-
cosamine, chondroitin sulfate, or shark cartilage in doses
that had not been stabilized within 6 months of the screen-
ing visit, and those with known alcohol abuse, intravenous
drug use, drug dependency, or history of signiﬁcant psychi-
atric illness in the previous 12 months were excluded.
Administration of oral corticosteroids within 2 months of
screening or intraarticular or periarticular corticosteroid or
hyaluronan injections into the study joint within 6 months
of screening were prohibited. Other exclusion criteria were
history of gastrointestinal or hepatic disease14, clinically ap-
parent inﬂammation of the study knee joint, secondary OA
of the study joint, history of acute inﬂammatory arthritis or
pseudogout of the study joint, or medical history, physical
examination, or radiographic evidence suggestive of other
types of arthritis, collagen vascular disease, or ﬁbromyalgia.This study was conducted at 47 investigational sites in
the United States between 17 April 2002 and 27 March
2003. The study was approved by the institutional review
board at each study center, and written informed consent
was obtained from each patient before entry into the study.
The study was conducted under the guidance of Good Clin-
ical Practice.
STUDY DESIGN
This was a multicenter, randomized, double-blind, paral-
lel-group, placebo-controlled study consisting of a screening
visit, a washout period during which use of all prestudy OA
pain medications was not permitted within ﬁve drug half-
lives of the baseline visit, a randomization visit correspond-
ing to baseline (with treatment allocation), and four study
visits while the assigned study medication was being ad-
ministered (at weeks 2, 4, 8, and 12). During the washout
period, patients could not take any prescription or over-
the-counter NSAID, acetaminophen, aspirin, or analgesic
in any form. Patients who had pain during the washout pe-
riod were permitted to take acetaminophen as rescue anal-
gesia up to 24 h before the baseline visit. In addition,
telephone contact was performed at weeks 1, 3, 5, 6, 7,
9, 10, and 11 to review all pertinent study issues, including
compliance with dosing of study medication and use of res-
cue medication.
Patient eligibility requirements at the screening visit were
a serum alkaline phosphatase (ALP) value less than or equal
to 1.5 times the upper limit of the reference range (ULRR),
alanine aminotransferase (ALT), aspartate aminotransfer-
ase (AST), total bilirubin, and blood urea nitrogen (BUN)
values less than or equal to 1.25 times the ULRR, a rheuma-
toid factor that was negative or less than 40 IU/mL, serum
creatinine level less than or equal to 1.5 mg/dL, and remain-
ing laboratory values within normal range. Following the
screening visit, all qualifying patients underwent a washout
period from their usual OA pain medications.
Patients attended a screening visit to verify eligibility and
to undergo study evaluation. OA history and disease condi-
tion were documented by asking the patient, ‘‘How would
you describe your history of OA pain when not taking anal-
gesic medications?’’ Response was based on a 5-point Lik-
ert scale ranging from none (0) to severe (4). The study
knee joint was assessed for redness, warmth, and effusion,
and the study hip joint for crepitus, restricted range of mo-
tion, and tenderness. Physical ability was categorized as
ACR functional class I, II, or III12,13. The diagnosis of OA
based on Kellgren and Lawrence radiographic entrance
criteria of grade 2 or 3 OA15 was conﬁrmed by review of a
recent (within the previous 6 months) weight-bearing,
anteroposterior radiograph of the symptomatic knee joint
or nonweight-bearing anteroposterior radiograph of the
symptomatic hip joint.
Qualiﬁed patients were randomly assigned to one of three
treatment groups. One group received acetaminophen ER
1950 mg daily in three divided doses, another group re-
ceived acetaminophen ER 3900 mg daily in three divided
doses, and the third group received placebo in three divided
doses. Patients were instructed to take the assigned study
medication every 8 h for 12 weeks or until study discontinu-
ation. Patients were guided on the appropriate use of self-
administered nonpharmacologic therapies for breakthrough
OA pain, and if pain relief was inadequate, propoxyphene
HCl (maximum dose, 390 mg/d) was permitted as the only
rescue analgesic medication and was to be used for no
more than 3 days in any 7-day period. Patients were not
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Fig. 1. Patient disposition.permitted to use rescue or other prescription analgesic
medications within ﬁve drug half-lives before follow-up visits
for efﬁcacy assessments.
Patients attended visits at the end of weeks 2, 4, 8, and
12, or upon early discontinuation from the study. At each
visit, the visual analog scale (VAS) version of the WOMAC,
laboratory evaluations, vital signs recording, patient global
assessment of response to therapy, and study joint assess-
ments were performed. Patients assessed response to ther-
apy by answering the question, ‘‘Considering the overalleffects of the study medication on your OA symptoms,
how would you rate your response to therapy today?’’ using
a 5-point scale of 0 (none e no good at all, ineffective), 1
(poor e some effect, but unsatisfactory), 2 (fair e reason-
able effect, but could be better), 3 (good e satisfactory ef-
fect with occasional episodes of pain and/or stiffness), or
4 (excellent e ideal response, virtually pain free). Patients
were instructed to bring all used and unused study medica-
tion blister cards and containers of propoxyphene HCl at
each visit to assess compliance and use of rescueTable I
Baseline demographic characteristics for the ITT population
Characteristic Acetaminophen
ER 3900 mg/d
(N¼ 160)
Acetaminophen
ER 1950 mg/d
(N¼ 158)
Placebo
(N¼ 165)
Total
(N¼ 483)
Gender (%)
Female:male ratio 71.3:28.8 57.6:42.4 71.5:28.5 66.9:33.1*
Mean age, y (SD) 61.7 (10.7) 63.1 (10.9) 61.8 (10.7) 62.2 (10.8)
Range 40e85 40e90 40e84 40e90
Mean weight, lb (SD) 208.2 (60.7) 193.6 (44.6) 202.7 (49.4) 201.6* (52.2)
Range 112e450 95e400 101e378 95e450
Mean screening height, in (SD) 65.5 (4.1) 66.4 (4.0) 65.5 (4.2) 65.8 (4.1)
Range 56e78 56.5e77 52e80 52e80
Mean body mass index, kg (SD) 34.1 (9.3) 30.8 (6.2) 33.2 (7.9) 32.7*
Median 31.7 29.9 31.8 31.0
Range 19.4e66.4 17.4e55.1 19.7e60.6 17.4e66.4
Race (%)
Caucasian 81.3 84.8 80.0 82.0
African American 10.0 4.4 11.5 8.7
Other 8.8 10.8 8.5 9.3
SD¼ standard deviation. *P< 0.05.
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of used and unused caplets of study medication and the
number of used propoxyphene HCl capsules at each visit.
EFFICACY ASSESSMENT
Primary efﬁcacy end points were mean change from
baseline through week 12 (or ﬁnal on-therapy visit) for
WOMAC pain and WOMAC physical function subscale
scores and mean patient global assessment of response
to therapy through week 12 (or ﬁnal on-therapy visit). Sec-
ondary efﬁcacy end points were mean change from base-
line through week 12 (or ﬁnal on-therapy visit) for
WOMAC stiffness subscale score and WOMAC total index,
and mean number of rescue medication capsules taken
each day while participating in the study. Safety assess-
ments consisted of monitoring vital signs, adverse events,
study joint assessments, and clinical laboratory determina-
tions at each visit.
Table II
Baseline disease characteristics for the ITT population
Characteristic Acetaminophen
ER 3900 mg/d
(N¼ 160)
Acetaminophen
ER 1950 mg/d
(N¼ 158)
Placebo
(N¼ 165)
OA site
Knee 130 128 135
Hip 30 30 30
Patient’s assessment of OA pain (%)
Moderate 26.9 23.4 21.2
Moderately severe 73.1 76.6 78.8
Redness of knee joint (%)
Absent 100 100 100
Knee joint warmth (%)
Absent 100 100 100
Knee effusion (%)
Absent 100 100 100
Hip joint restricted range of motion (%)
Absent 100 100 100TREATMENT ALLOCATION
Of the 483 patients eligible for randomization, 160 pa-
tients were assigned to acetaminophen ER 3900 mg/
d (2 650-mg acetaminophen ER caplets administered
orally every 8 h; McNeil Consumer Products Co, Fort
Washington, PA), 158 patients were assigned to acetamin-
ophen ER 1950 mg/d (1 650-mg acetaminophen ER cap-
let plus one placebo caplet administered orally every 8 h),
and 165 were assigned to receive placebo (two placebo
caplets administered orally every 8 h). The placebo caplets
were supplied by a McNeil-designated contractor and were
similar in color, size, and shape to the acetaminophen ER
caplets.
STATISTICAL ANALYSES
A sample size of 155 patients per treatment group was
needed to ensure 90% power to detect a difference means
of 10 mm on the WOMAC pain domain VAS assuming
a standard deviation of 27 using a two group t test with
a 0.05 two-sided signiﬁcance level.
Analysis of primary and secondary efﬁcacy end points
was based on the intent-to-treat (ITT) population, which in-
cluded all randomized patients; data from speciﬁc visits
were excluded when (1) the visit occurred at least 1 day af-
ter discontinuation from the study, or (2) when a visit oc-
curred after (a) the patient used propoxyphene HCl and/or
another rescue medication indicated for OA pain for more
than 3 days in any 7 day period, (b) the patient took more
than six propoxyphene HCl caplets in any single calendar
day, or (c) the patient received intraarticular or periarticular
corticosteroid or hyaluronan injections of the study joint dur-
ing the 12 week study period. Safety analysis was con-
ducted on all randomized patients who took at least one
dose of study medication. In this study, the ITT and safety
populations were identical.
Analysis of covariance (ANCOVA) models with treatment
and investigator as ﬁxed effects and the corresponding
baseline value as a covariate were used to analyze meanTable III
Average change from baseline values for the primary and secondary efficacy outcome measures in the ITT population
End point Acetaminophen ER
3900 mg/d
(N¼ 160)
Acetaminophen ER
1950 mg/d
(N¼ 158)
Placebo
(N ¼ 165)
Mean WOMAC pain
subscale score (SD)
Baseline 68.9 (19.7) 67.9 (16.5) 66.3 (19.3)
Treatment period 42.4 (24.8) 45.1 (22.7) 46.7 (25.8)
Average change
from baseline
26.5 (25.5) 22.8 (21.6) 19.6 (22.5)
Mean WOMAC physical
function subscale score (SD)
Baseline 69.1 (18.3) 65.9 (18.9) 65.3 (19.4)
(N¼ 164)
Treatment period 44.2 (25.1) 47.1 (24.9) 47.5 (25.8)
Average change
from baseline
24.9 (24.6) 18.8 (21.9) 17.8 (22.3)
Mean WOMAC stiffness
subscale score (SD)
Baseline 69.8 (20.9)
(N¼ 148)
67.3 (18.8)
(N¼ 150)
69.5 (19.6)
(N¼ 145)
Treatment period 44.5 (24.3) 47.1 (24.6) 48.9 (25.7)
Average change
from baseline
25.3 (27.3) 20.2 (24.0) 20.6 (24.8)
Mean WOMAC total
index score (SD)
Baseline 69.1 (18.1) 66.5 (17.4) 65.8 (18.6)
(N¼ 164)
Treatment period 44.0 (24.8) 46.8 (24.0) 47.5 (25.3)
Average change
from baseline
25.1 (24.5) 19.7 (21.2) 18.2 (22.0)
All WOMAC subscale scores were normalized to a scale of 0 to 100.
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Fig. 2. Mean change from baseline through week 12 for WOMAC pain and physical function subscale scores. For WOMAC pain, the treat-
ment-by-baseline pain term is included in the model; pairwise comparisons are made at the average value of baseline pain (67.68).change from baseline through week 12 (or ﬁnal on-therapy
visit) in WOMAC pain subscale, physical function subscale,
stiffness subscale, and total index. The average subject’s
assessment of response to therapy was analyzed using
an ANCOVA model with treatment and investigator as ﬁxed
effects and the WOMAC pain subscale score at baseline as
a covariate; if the covariate term was not signiﬁcant, it was
dropped from the model. The treatment-by-investigator and
treatment-by-covariate interactions were also evaluated. If
the P value for the interaction term(s) was greater than
0.10, the interaction term(s) was not included in the ﬁnal
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Fig. 3. Mean patient global assessment through week 12.model. Statistical comparisons of the two active treatment
groups with placebo were made with respect to least
squares means. The least squares mean adjusts for factors
in the statistical model such as site variation and baseline
covariates. No statistical comparisons were made between
the two active treatment groups because the purpose of the
study was to determine the effective dose compared with
placebo. For the primary efﬁcacy variables, study joint
and the interaction term of treatment-by-study joint were in-
troduced into the statistical models to determine if treatment
behaves differently depending on the study joint.
Comparability among treatment group demographics was
assessed using one-way analysis of variance (ANOVA) for
continuous variables (age, weight, height, body mass index
[BMI]) and Chi-square tests for categorical variables (race,
sex, baseline clinical measures). The mean number of res-
cue medication capsules taken per day was analyzed using
an ANOVA model, with treatment and investigator as ﬁxed
effects. Fisher’s exact test was used to analyze compari-
sons of adverse events, the proportion of patients using
more than the allowed amount of rescue medication, and
the proportion of patients discontinuing the study because
of a lack of efﬁcacy.
Results
BASELINE CHARACTERISTICS
Eight hundred ﬁfty-six patients were screened, 483 of
whom met clinical inclusion criteria and were randomized
to treatment; 347 (72%) patients completed the study
(Fig. 1). Baseline characteristics of the patients included
in the ITT population are summarized in Tables I and II.
All groups were similar with the exception of a statistically
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Least squares means of average change from baseline through week 12 for WOMAC scores in the ITT population
End point Acetaminophen
ER 3900 mg/d
(N¼ 160)
Acetaminophen
ER 1950 mg/d
(N¼ 158)
Placebo
(N ¼ 165)
P value*
WOMAC pain
subscale scorey
25.9 (1.76) 22.5 (1.77) 19.8 (1.74) 0.012
WOMAC physical
function subscale scorey
24.2 (1.80) 19.0 (1.80) 18.2 (1.77) (N¼ 164) 0.016
WOMAC stiffness
subscale scorey
25.2 (2.0) (N¼ 148) 21.1 (2.0) (N¼ 150) 20.5 (2.0) (N¼ 145) 0.088
WOMAC total
index scorey
24.5 (1.8) 19.8 (1.8) 18.6 (1.8) (N¼ 164) 0.015
*Acetaminophen 3900 mg/d vs placebo.
yLeast squares mean change from baseline (standard error).signiﬁcant difference among treatment groups with respect
to male:female ratio (P¼ 0.0104), baseline weight
(P¼ 0.0421), and BMI (P¼ 0.0008). Speciﬁcally, the per-
centage of women, the mean body weight, and the mean
BMI were lower in the acetaminophen ER 1950-mg/d group
than in the other two groups. Overall, the mean age of the
study population was 62.2 years, and the study population
was mainly women (67%) and Caucasian (82%). Approxi-
mately 75% of the patients in each treatment group had
moderately severe OA pain. Thirty patients in each treat-
ment group had hip OA; the remaining 393 patients had
knee OA. Baseline values for primary and secondary efﬁ-
cacy outcome measures for all three treatment groups are
shown in Table III.
EFFICACY RESULTS
Acetaminophen ER 3900 mg/d was superior to placebo
for all three primary end points, as indicated by a signiﬁ-
cantly greater mean change from baseline in WOMAC
pain subscale score, WOMAC physical function subscale
score (Fig. 2), and patient global assessment (Fig. 3). Im-
provements in WOMAC pain subscale score, WOMAC
physical function subscale score, and patient global re-
sponse were statistically superior (P< 0.05) for acetamino-
phen 3900 mg/d compared with placebo from weeks 4
through 12. In the analysis of the WOMAC pain subscale,
the signiﬁcance level (P¼ 0.0685) of the baseline paine
treatment interaction term implies that the 3900-mg/d treat-
ment may perform better at higher levels of baseline pain.
As baseline pain increases, the change from baseline
also increases, with the regression lines crossing at a base-
line pain score of approximately 45. Acetaminophen ER
1950 mg/d was signiﬁcantly superior to placebo with re-
spect to one primary end point of patient’s global
Table V
Number and percent of patients with the most commonly reported
(5% in any one treatment group) adverse events
Preferred
term
Acetaminophen
ER 3900 mg/d
(N¼ 160) n (%)
Acetaminophen
ER 1950 mg/d
(N¼ 158) n (%)
Placebo
(N ¼ 165)
n (%)
P value*
Headache 9 (5.6) 7 (4.4) 5 (3.0) 0.502
Infection 9 (5.6) 6 (3.8) 9 (5.5) 0.752
Pain 8 (5.0) 13 (8.2) 8 (4.8) 0.394
Diarrhea 9 (5.6) 7 (4.4) 4 (2.4) 0.331
*P value based on Fisher’s exact test. N¼ total number of patients
in safety population within a treatment group; n¼ number of patients
reporting an adverse event.assessment of response to therapy, with the difference
noted as early as week 4 (P< 0.05). Primary efﬁcacy re-
sults did not differ between hip or knee based on ANCOVA
analyses. No analysis was conducted to assess effects by
gender.
In the secondary efﬁcacy analyses, the mean change
from baseline for WOMAC total index in the acetaminophen
ER 3900-mg/d group was signiﬁcantly greater than in the
placebo group (Table IV); signiﬁcant changes were noted
at each time point after week 2 (P< 0.05). No other statis-
tically signiﬁcant differences among treatment groups
were noted for secondary end points. There was no signif-
icant difference among treatment groups in the mean num-
ber of capsules of rescue medications used.
The overall rate of withdrawal from the study was slightly
higher in the placebo group (32.7%) than in the acetamino-
phen ER groups (28.1% for the 3900-mg/d group and
23.4% for the 1950-mg/d group). The most frequent primary
reason for discontinuation in all treatment groups was lack
of efﬁcacy, which was reported at a higher rate in the pla-
cebo group (20.6% of patients) than in the acetaminophen
ER groups (16.9% for the 3900-mg/d group and 10.1% for
the 1950-mg/d group) (Fig. 1).
ADVERSE EVENTS
There were no signiﬁcant differences among the groups
in the percentage of subjects with adverse events reported
or the percentage of patients with serious adverse events.
Overall, 44.4% of patients in the acetaminophen ER
3900-mg/d group, 44.9% of patients in the acetaminophen
ER 1950-mg/d group, and 40.0% of patients in the placebo
group reported one or more adverse events. The number
and percent of patients with commonly reported adverse
events (at least 5% of patients in any one treatment group)
by treatment group are summarized in Table V. Adverse
events considered by physicians to be related to treatment
were reported by 8.1% of patients in the acetaminophen ER
3900-mg/d group, 9.5% of patients in the acetaminophen
ER 1950-mg/d group, and 4.8% of patients in the placebo
group (P¼ 0.25). Overall, eight patients reported serious
adverse events (three each in the acetaminophen ER
3900-mg/d and 1950-mg/d groups and two in the placebo
group); none of the adverse events were considered to be
drug related. There was one death in the study (a patient
treated with placebo) as a result of an auto accident; the
death was not considered to be drug related.
Three patients (1.9%) in the acetaminophen ER 3900-
mg/d group had either AST and/or ALT levels greater
than three times the ULRR. In two of these three patients,
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tered could have caused elevations in liver function tests.
Liver function tests returned to normal in one of the two
who continued treatment and in the other patient after dis-
continuation of acetaminophen ER. No speciﬁc causative
factors were identiﬁed in the third patient, however; liver
function tests returned toward normal while the patient re-
mained on drug treatment and in the study. Additionally,
four patients on acetaminophen 3900 mg/d, two patients
on acetaminophen 1950 mg/d, and two patients on placebo
had minor transient increases in ALT and/or AST between
1.5 and three times the ULRR. None demonstrated progres-
sive increases in liver function tests.
Discussion
This study demonstrated that acetaminophen ER
3900 mg/d administered for up to 12 weeks was superior
to placebo for all three primary end points (WOMAC pain
score, WOMAC physical function score, and patient global
assessment of response to therapy), as well as for the sec-
ondary end point of WOMAC total index. Signiﬁcant differ-
ences were noted at every time point after week 2 and
continued through week 12. Acetaminophen ER 1950 mg/d
was superior to placebo with respect to patient global assess-
ment of response to therapy. All study treatments were well
tolerated, and the overall incidence of adverse events was
similar among treatment groups.
Serum transaminase elevations have been observed in
other clinical studies conducted with acetaminophen16e18.
The few elevations that were >3 times the ULRR in this
study did not result in serious complications, similar to other
published studies16e18. In this trial, as in others, comorbid
diseases or concomitant medications may have caused el-
evations in liver function tests.
This study is the ﬁrst published clinical trial showing the
superiority of an ER formulation of acetaminophen over pla-
cebo. These results are consistent with the ACR guidelines
for treatment of OA, which recommend the use of acetamin-
ophen as ﬁrst-line therapy for the treatment of OA pain of
the hip or knee.
The study has some limitations. Because the purpose
was to determine the effective dose of a formulation of acet-
aminophen not previously evaluated for hip or knee OA and
not to compare the formulation to other treatments, a pla-
cebo arm was used instead of an active control arm, such
as an NSAID. Similarly, statistical comparisons between
the two acetaminophen groups were not conducted be-
cause the purpose was to determine the least effective
dose of acetaminophen. The inclusion criteria required pa-
tients to have had a prior response to acetaminophen. An
unselected population assuredly would not have had as
good a response to acetaminophen, thus it would have
been difﬁcult to determine whether the formulation was ef-
fective. The study was successful because it showed that
the lower dose was not as effective as the higher dose.
The authors feel that requiring a prior response to acetamin-
ophen is analogous to the ‘‘ﬂare’’ design used in trials of
most antiinﬂammatory agents.
Although there are limited data available on the long-term
use of acetaminophen ER and on the efﬁcacy and safety of
acetaminophen ER in comparison with an NSAID, data are
available for IR acetaminophen demonstrating that it is as
effective as NSAIDs10,11,18,19. In a randomized, double-
blind, clinical trial of 184 patients with chronic knee pain
caused by OA, the efﬁcacy of acetaminophen 4000 mg/
d was demonstrated to be equivalent to that of eitheribuprofen 1200 or 2400 mg/d in the short-term treatment
of OA10. Williams and colleagues also demonstrated in
a randomized, double-blind, clinical trial equal analgesic ef-
ﬁcacy and safety between acetaminophen 2600 mg/d and
naproxen 750 mg/d in the treatment of OA of the knee11.
Of note, recently published trial results also provided data
on the efﬁcacy and safety of acetaminophen. A multicenter,
randomized, double-blind, parallel-group study of patients
with OA of the knee or hip demonstrated that sustained reg-
ular use of acetaminophen for up to 12 months at recom-
mended doses of 4000 mg/d reduced WOMAC pain,
stiffness, and physical function scores to an extent similar
to that of naproxen 750 mg/d without evidence of clinically
important adverse effects18.
The current study demonstrates the superiority of acet-
aminophen over placebo and is consistent with a previous
study performed by Amadio and Cummings19, which con-
cluded that patients taking acetaminophen 4000 mg/d had
signiﬁcant improvement in symptoms (e.g., tenderness,
pain at rest, and pain on motion) during a 6-week period
as compared with patients receiving placebo.
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